Uricosurics: control of uric acid synthesis
The primary representative of drugs affecting purine metabolism is allopurinol (Allopurinolum). Chemically, this compound is an exact structural analogue of hypoxanthine. On exams and in test questions, this fact is frequently tested: students need to clearly differentiate hypoxanthine from other related molecules such as guanine, adenine, or xanthine. It is this structural similarity to hypoxanthine that allows allopurinol to successfully interfere with the body's natural biochemical cascades.
The main pharmacological target of allopurinol is the enzyme xanthine oxidase. Acting as a specific blocker of this enzyme, the drug purposefully disrupts the synthesis of uric acid. Since uric acid production is halted, allopurinol is classified strictly as a uricostatic agent (from the Greek "stasis" — halting).
In clinical practice, it is extremely important to understand allopurinol's place in the treatment regimen. Its main and most crucial indication is baseline therapy. The drug is prescribed for long-term prevention of gout attacks. Students often make a grave mistake by assuming it is used in the acute phase: it must be firmly remembered that allopurinol is absolutely not used for direct treatment and pain relief during an acute gouty attack.
Uricosuric agents: enhancement of excretion
The second major group of drugs for gout control is uricosuric agents. A prominent representative of this pharmacological group is benzbromarone (Benzbromaronum).
Unlike uricostatics, benzbromarone does not interfere with enzyme activity and does not stop uric acid synthesis. Its mechanism of action is realized at the level of the excretory system, specifically in the renal tubules. The drug specifically blocks the process of uric acid reabsorption (back-diffusion). As a result of this physiological block, uric acid does not return to the systemic circulation but is actively excreted from the body in the urine.
Interestingly, in complex clinical situations, the pharmacological properties of different groups can be advantageously combined. Combination therapy is permitted, in which benzbromarone is used together with allopurinol. This combination makes it possible to simultaneously target two links of pathogenesis: one drug inhibits the formation of the pathological agent, while the second forces the excretion of what has already managed to form.
Differential diagnosis and common pitfalls
When studying the pharmacology of gout medications, special attention is paid to the differential diagnosis of drugs and understanding their side effects. One of the most common misconceptions is related to diuretics.
It might seem logical that agents increasing urine output should promote uric acid excretion. However, classical diuretics such as furosemide (Furosemidum), hydrochlorothiazide (Hydrochlorothiazidum), and the osmotic diuretic mannitol (Mannitolum) do not belong to uricosuric agents. Moreover, their use often causes the exact opposite, undesirable effect — hyperuricemia (a pathological increase in blood uric acid concentration), which can trigger a severe exacerbation of gout.
Also, when differentiating drug groups, it is necessary to clearly distinguish their mechanisms and pharmacological classification. As already mentioned, allopurinol is exclusively a uricostatic agent. In test questions, it is often falsely presented as a uricosuric agent, a COX inhibitor, or colchicine (Colchicinum). This is incorrect: allopurinol has no direct effect on renal tubular reabsorption and has completely different sites of action compared to COX inhibitors and colchicine.
Briefly: answers to topical questions
Which drugs belong to the group of uricosuric agents?
The group of uricosuric agents includes drugs that increase uric acid excretion by blocking its reabsorption in the renal tubules.
- Benzbromarone — blocks uric acid reabsorption, promoting its excretion.
- Sulfinpyrazone — competes with uric acid for transport systems in the kidneys.
- Probenecid — enhances renal excretion of urates.
Which drugs are used to relieve an acute gout attack?
To relieve an acute gout attack, drugs aimed at suppressing inflammation and relieving pain are used.
- Nonsteroidal anti-inflammatory drugs (e.g., ibuprofen).
- Glucocorticoids; intra-articular injections are contraindicated until joint infection is definitively ruled out.
- Colchicine — most effective when used within the first 12 hours after the onset of an exacerbation.
- Interleukin-1 blockers (e.g., anakinra) — a potential option for relieving an attack.
What side effects are characteristic of allopurinol?
Allopurinol is characterized by a wide range of adverse drug reactions affecting various body systems.
- Allergic and skin reactions — dermatitis, pruritus, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis.
- Blood system — anemia, thrombocytopenia, eosinophilia, leukopenia, leukocytosis.
- Urinary system — acute renal failure, interstitial nephritis.
- Musculoskeletal system — myopathy, myalgia, arthralgia.
- Other effects — paradoxical exacerbation of gout in the first weeks of therapy, dyspepsia, drowsiness, headache, and peripheral edema.
What are the indications for prescribing allopurinol?
Allopurinol is prescribed to lower uric acid levels and prevent associated complications.
- Baseline therapy for gout — prevention of attacks in patients with a confirmed diagnosis (2 or more attacks per year) during the interictal period with normal renal function.
- Prevention and treatment of tumor lysis syndrome — in patients with massive tumor burden receiving anticancer therapy.
- Prevention of secondary hyperuricemia and urate nephropathy — in patients receiving chemotherapy for malignant neoplasms.
To avoid confusing the groups: Uricostatics (allopurinol) put uric acid synthesis "on pause" (stasis). Uricosurics (benzbromarone) are linked to urine (urina) — they drive acid out through the kidneys.
Class and exam questions
Why is allopurinol not prescribed during an acute attack of gout?
Allopurinol is a baseline therapy drug intended exclusively for long-term prophylaxis. It is not used for the immediate treatment and relief of acute pain during an attack.
What is the fundamental difference between uricostatics and uricosurics?
Uricostatics (allopurinol) block the enzyme xanthine oxidase and disrupt uric acid synthesis. Uricosuric agents (benzbromarone) work in the kidneys — they block tubular reabsorption of acid, promoting its excretion.
How do diuretics affect uric acid levels?
Diuretics (furosemide, hydrochlorothiazide, mannitol) are not uricosuric drugs. On the contrary, they often cause the opposite effect — hyperuricemia, retaining uric acid in the body.
What else to study on this topic
- The biochemical cascade of purine base conversion: from hypoxanthine to uric acid.
- The role of the enzyme xanthine oxidase in purine metabolism and mechanisms of its inhibition.
- The pathophysiology of hyperuricemia development during the administration of loop, thiazide, and osmotic diuretics.
- Pharmacological rationale for combination therapy with allopurinol and benzbromarone.
- Analysis of test distractors: pharmacological profile of COX inhibitors and colchicine in the context of gout therapy.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Pharmacology of Gout Drugs" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Antigout drugs"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.